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In Brief
Breast cancers frequently develop
resistance to anti-estrogen treatment,
which makes it imperative to
understanding how therapy resistance
develops. Here, Simo˜es et al. show that
combining standard anti-estrogen
therapies with anti-Notch4 drugs
targeting breast cancer stem cells should
improve treatment of ER+ breast cancer
patients by preventing relapse due to
therapy resistance.
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Breast cancers (BCs) typically express estrogen
receptors (ERs) but frequently exhibit de novo or ac-
quired resistance to hormonal therapies. Here, we
show that short-term treatment with the anti-estro-
gens tamoxifen or fulvestrant decrease cell prolif-
eration but increase BC stem cell (BCSC) activity
through JAG1-NOTCH4 receptor activation both in
patient-derived samples and xenograft (PDX) tu-
mors. In support of this mechanism, we demonstrate
that high ALDH1 predicts resistance in women
treated with tamoxifen and that a NOTCH4/HES/
HEY gene signature predicts for a poor response/
prognosis in 2 ER+ patient cohorts. Targeting of
NOTCH4 reverses the increase in Notch and BCSC
activity induced by anti-estrogens. Importantly, in
PDX tumors with acquired tamoxifen resistance,
NOTCH4 inhibition reduced BCSC activity. Thus,
we establish that BCSC and NOTCH4 activities pre-
dict both de novo and acquired tamoxifen resistance
and that combining endocrine therapy with target-
ing JAG1-NOTCH4 overcomes resistance in human
breast cancers.
INTRODUCTION
Resistance to endocrine therapies such as selective estrogen
receptor (ER) modulators (SERMs; e.g., tamoxifen), selective
ER downregulators (SERDs; e.g., fulvestrant), and the aromatase1968 Cell Reports 12, 1968–1977, September 29, 2015 ª2015 The Ainhibitors is seen in 50%–60% of early breast cancer (BC) cases
and develops in almost all patients with advanced disease
(Davies et al., 2011; Palmieri et al., 2014).
Evidence suggests that tumor-initiating or cancer stem-like
cells (CSCs) are responsible for tumor recurrence after chemo-
and endocrine therapy (Li et al., 2008; Creighton et al., 2009). Al-
Hajj et al. (2003) were the first to show that tumor-initiating cells
were capable of recapitulating the original tumor phenotype
when transplanted into immunodeficient mice. In vitro functional
assays forBCstemcell (BCSC)activity includealdehydedehydro-
genase 1 (ALDH1) enzyme activity and the capacity to formclono-
genic mammospheres in suspension culture (Ginestier et al.,
2007). It has been demonstrated that the BCSC population is ER
negative/low and resistant to the direct effects of endocrine ther-
apy (Simo˜es et al., 2011; Harrison et al., 2013; Piva et al., 2014).
We have shown that aberrant Notch activation transforms
normal breast cells, is found in pre-invasive and invasive human
BCs, and correlates with early recurrence (Stylianou et al., 2006;
Farnie et al., 2007). Moreover, we reported that inhibition of
Notch signaling, particularly NOTCH4 receptor, reduced BCSC
activity (Harrison et al., 2010).
Here, using patient-derived ER+ BC samples and patient-
derived xenografts (PDXs), we report that short-term treatment
with endocrine therapies enriches for JAG1-NOTCH4-regulated
BCSCs, suggesting that these effects are not through genetic
selection. Furthermore, we show that ALDH1 expression and
NOTCH4 activation in human primary tumors are predictive of
resistance to endocrine treatments. Finally, we demonstrate
that NOTCH inhibition in vivo reduces BCSC activity in long-
term acquired resistant PDX tumors. Thus, we propose that in-
hibiting Notch signaling will help overcome endocrine therapy
resistance and recurrence in ER+ BC.uthors
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Figure 1. Tamoxifen or Fulvestrant Treat-
ment of ER+ Patient-Derived Samples and
PDXs Selectively Enriches for Cells with
CSC Properties
High BCSC frequency is associated with worse
outcomes for tamoxifen-treated BC patients.
(A) Mammosphere self-renewal of freshly iso-
lated ER+ early and metastatic patient-derived
samples. Primary mammospheres cultured in
the presence of ethanol (Control) or 106 M
4-hydroxy-tamoxifen (Tamoxifen) were dissoci-
ated and re-plated in secondary mammosphere
suspension culture for a further 7–9 days
to measure self-renewal of mammosphere-
initiating cells treated in the first generation.
p value was calculated with Wilcoxon signed-
rank test.
(B) Representative micrographs of metastatic BC
cells before fluorescence-activated cell sorting
(FACS) analysis of ALDH1 enzymatic activity
(ALDEFLUOR assay). ALDH-positive cells were
discriminated from ALDH-negative cells using the
ALDH inhibitor DEAB.
(C) Percentage of ALDH-positive cells in nine ER+
metastatic BC patient-derived samples. Cells
were grown in adherence with ethanol (Control),
tamoxifen (106 M), or fulvestrant (107 M) for 7–
9 days. Arrows indicate fold change greater than
20% compared to control.
(D–G) Early (HBCx34) and metastatic (BB3RC31)
BC estrogen-dependent PDX tumors treated
in vivo for 14 days with tamoxifen (10 mg/kg/day,
oral gavage; red bars) or fulvestrant (200 mg/
kg/week, subcutaneous injection; blue bars).
Gray bars correspond to vehicle control. FFPE,
formalin-fixed paraffin-embedded. (E) Represen-
tative micrographs and quantification of Ki67
expression determined by immunohistochemistry
(IHC). (F) Percentage of MFE. (G) ALDH-positive
cells (%) determined using the ALDEFLUOR
assay.
(H) ALDH1 expression was assessed by immuno-
histochemistry in breast tumor epithelial cells,
and the percentage of positive cells was
scored. Representative micrographs of ALDH-
high (ALDHhi) and -low (ALDHlo) epithelial expres-
sion are shown. Kaplan-Meier curves represent
cumulative survival for the ALDHlo population and
ALDHhi population of a cohort of 322 pre-meno-
pausal ER+ BC patients who participated in a
randomized trial of 2 years of adjuvant tamoxifen
treatment versus no systemic treatment (control). Vertical bars on survival curves indicate censored cases. p values are based on a log-rank (Mantel-Cox) test
of equality of survival distributions.
Scale bars, 100 mm. Data are represented as mean ± SEM. *p < 0.05; **p < 0.01.
See also Figure S1.RESULTS
BCSC Activity Is Enriched by Tamoxifen and Fulvestrant
We tested the effect of the anti-estrogen tamoxifen on the mam-
mosphere-forming efficiency (MFE) of patient-derived ER+ tu-
mor cells and found that tamoxifen increases mammosphere
self-renewal by about 2-fold (Figures 1A, S1A, and S1B). Next,
we investigated ALDH activity, another functional assay for
CSCs, in nine patient samples treated with tamoxifen or fulves-Cell Reptrant and showed significant increases in ALDH enzymatic activ-
ity in seven patients (Figures 1B and 1C). These data suggest
that endocrine therapies, given for a period of a few days, enrich
for stem cell activity.
Then, we tested the in vivo impact of endocrine therapies on
stem cell activity in ER+ BC using PDXs grown subcutaneously
in mice. We used both an early (treatment-naive; early BC)
and a metastatic ER+ PDX tumor that both maintain biological
characteristics (such as the expression of ER and estrogenorts 12, 1968–1977, September 29, 2015 ª2015 The Authors 1969
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Figure 2. Tamoxifen or Fulvestrant Treatment Upregulates Notch Target Genes in Patient-Derived Samples and PDXs
JAG1-NOTCH4 receptor signaling in ALDH-positive cells drives Notch activity in endocrine-resistant BC.
(A and B) Expression of Notch target genes HEY1 and HES1 was assessed by real-time qPCR analysis and compared to control to determine fold change. (A)
Metastatic BC patient-derived cells were treated for 7–9 days with ethanol (control), tamoxifen (106 M), or fulvestrant (107 M) and a correlation between fold
change of expression of HEY1 andHES1 and fold change of percentage of ALDH-positive cells is shown. (B) Early (HBCx34) andmetastatic (BB3RC31) BC PDXs:
the effect of in vivo treatment for 14 days with tamoxifen (10mg/kg/day, oral gavage) or fulvestrant (200mg/kg/week, subcutaneous injection) onHEY1 andHES1.
(legend continued on next page)
1970 Cell Reports 12, 1968–1977, September 29, 2015 ª2015 The Authors
dependence) of the patient primary tumor from which they were
derived (Figures S1D and S1E). The estrogen dependence of the
HBCx34 PDX model (early BC) has been previously reported
(Cottu et al., 2012). Using a 14-day in vivo ‘‘window’’ treatment
(Figure 1D), we showed that both tamoxifen and fulvestrant treat-
ment decrease proliferation (Figure 1E). However, there is an in-
crease in MFE and ALDH enzymatic activity (Figures 1F and 1G),
suggesting a mechanism for endocrine resistance driven by
enrichment for a stem cell phenotype.
The mechanism for this enrichment by anti-estrogens may be
partly explained by more than 90% of sorted ALDH-positive
cells being ER negative (Figure S1C). Thus, we hypothesized
that frequency of ALDH-positive cells would predict for res-
ponse to tamoxifen treatment, and we analyzed ALDH1 in 322
ER+ BC samples taken prior to a randomized trial of tamoxifen
versus no systemic treatment. ALDH1 percentage dichotomized
at the median value predicted benefit from tamoxifen so that
improvement in survival (i.e., a response to treatment) was
only seen in women with low epithelial ALDH1 expression (Fig-
ure 1H; Table S3). We saw no significant difference in recurrence
between control treated patients with high versus low ALDH1
expression (p = 0.59). These data, from a prospective random-
ized trial, establish for the first time that ALDH-positive cell fre-
quency predicts response to tamoxifen treatment, suggesting
that stem cell numbers may be responsible for de novo endo-
crine resistance.
Tamoxifen or Fulvestrant Treatment Upregulates Notch
Target Genes
We analyzed the patient-derived BC cells that were treated with
tamoxifen and fulvestrant in Figures 1B and 1C and found that
increased numbers of ALDH-positive cells were strongly corre-
lated to increased expression of Notch target genes (HEY1 and
HES1) (Figure 2A). In addition, the BC PDX tumors treated in vivo
with tamoxifen or fulvestrant (Figure 1D) for 2 weeks showed
increased HEY1 and HES1 expression (Figure 2B), supporting
an increased role for the Notch signaling pathway after endo-
crine therapies.
In ER+ cell lines (MCF-7, T47D, and ZR-75-1) in vitro, treat-
ment with tamoxifen or fulvestrant for 6 days preferentially
increased expression of HEY1 and HES1 (Figure S2A). Similarly,
in tamoxifen-resistant (TAMR) or fulvestrant-resistant (FULVR)
MCF-7 models, which have acquired resistance after long-
term tamoxifen or fulvestrant treatment, we found upregulation
of Notch target genes and increased Notch transcriptional activ-
ity (Figure S4A).(C) NOTCH4, HES1, and JAG1 protein expression levels determined by western b
the loading control.
(D) NOTCH4, HES1, and JAG1 protein expression levels were determined by wes
were treated with tamoxifen or fulvestrant for 6 days before ALDH sorting.
(E) Wild-type MCF-7 cells (filled bars) and a CRISPR clone containing a disrupti
ethanol (Control, gray bars), 106 M tamoxifen (red bars), and 107 M fulvestrant (
after treatments was compared to that of the wild-type cells.
(F and G) NICD4 and JAG1 rescue tamoxifen- or fulvestrant-inhibited growth: cell
(F) NICD4-GFP, (G) JAG1-GFP, or GFP control incubated with tamoxifen or fulvest
control ethanol. p values are for the 5-day treatment.
Data are represented as mean ± SEM. *p < 0.05; **p < 0.01.
See also Figures S2 and S4.
Cell RepJAG1 andNOTCH4Receptor Signaling Drives Endocrine
Resistance
Next, we assessed the expression of Notch receptors and
ligands in parental, TAMR, and FULVR cell lines. NOTCH4 and
its intracellular domain (ICD) were upregulated while NOTCH1,
-2, and -3 were downregulated (Figure S4B) in the resistant
versus parental cell lines. We found the Notch ligand JAG1 to
be highly expressed in both resistant models (Figure S4B), while
expression of the other four ligands was either unchanged (DLL1
and DLL4; Figure S4B) or absent (JAG2 and DLL3; data not
shown). JAG1 and NOTCH4-ICD were also upregulated after a
14-day window treatment of PDXs in vivo, and after short-term
treatment with tamoxifen or fulvestrant of MCF-7 cells in vitro,
suggesting that activation of Notch signaling (demonstrated by
increased HES1 expression) is an early event in the acquisition
of endocrine resistance (Figures 2C and S2B). Importantly,
JAG1, NOTCH4-ICD, and HES1 are expressed at higher levels
in ALDH-positive cells, which suggests JAG1-NOTCH4 signaling
between ALDH-positive cells (Figure 2D).
To further confirm the role of NOTCH4 activity in endocrine
resistance and the stem cell phenotype, we analyzed loss-of-
and gain-of-function phenotypes for NOTCH4-ICD in MCF-7
cells. Genomic disruption of exon 2 of NOTCH4 by using a
CRISPR approach led to loss of protein expression (Figures
S2C–S2E) and a significant inhibition of MFE and ALDH-positive
cells, especially after tamoxifen and fulvestrant treatments
(Figure 2E). In contrast, overexpression of NOTCH4-ICD or
JAG1 conferred tamoxifen and fulvestrant resistance in parental
MCF-7 cells (Figures 2F and 2G).
Overall, these results indicate that JAG1 ligand and cleavage
of NOTCH4-ICD may be responsible for Notch signaling activa-
tion after endocrine treatment, which is in agreement with recent
reports that NOTCH4 expression is increased in TAMR cell lines
(Yun et al., 2013; Lombardo et al., 2014).
GSI RO4929097 Abrogates Tamoxifen- and Fulvestrant-
Stimulated CSC Activity
In order to inhibit NOTCH4 signaling, we used the gamma-secre-
tase inhibitor (GSI) RO4929097, which we found to be effective in
reducing levels of the active NOTCH4 ICD in endocrine-resistant
models (Figure S4C). RO4929097 inhibited HEY1 and HES1
expression, as well as CBF1-Notch transcriptional activity in
TAMR and FULVR cell lines, but not in parental MCF-7 cells
(Figure S4D). Therefore, we tested whether RO4929097 would
abrogate increases in MFE and ALDH-positive cells induced
in vivo by anti-estrogens administered in short-term windowlot in metastatic (Met) (BB3RC31) BC PDX. b-actin was used as a reference for
tern blot in MCF-7 ALDH-negative and ALDH-positive sorted cells. MCF-7 cells
on of NOTCH4 exon 2 (N4EX2 cells, hatched bars) treated in adherence with
blue bars) for 6 days. N4EX2 cells’ fold change of MFE and ALDH-positive cells
number (using sulforhodamine B [SRB] assay, y axis) of MCF-7 overexpressing
rant for 1, 3, and 5 days (x axis) compared to the respective cell line treatedwith
orts 12, 1968–1977, September 29, 2015 ª2015 The Authors 1971
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treatments, using the same estrogen-dependent ER+ PDX tu-
mors as in Figures 1D–1G. Tamoxifen and fulvestrant treatments
reduced tumor growth and proliferation (Figures S3A and S3B)
while increasing both MFE and ALDH activity (Figures 3A and
3B). RO4929097 had no impact on growth or proliferation
(% Ki67; Figure S3B) but significantly inhibited endocrine-stimu-
lated MFE and ALDH activity (Figures 3A and 3B). The gold
standard for functionally determining tumor-initiating cells is
xenograft formation in secondary mouse hosts, which we per-
formed using dissociated cells from PDX tumors treated in vivo
with anti-estrogens and/or RO4929097. Cells isolated from tu-
mors treated in vivo with RO4929097 had significantly reduced
tumor-initiating capacity 90 days post-implantation (Figure 3C).
Furthermore, the stimulation of tumorigenicity following in vivo
tamoxifen and fulvestrant treatment was completely reversed
by RO4929097 (Figure 3C). Overall, these data suggest that
BCSCs, measured by tumor-initiating activity and enriched by
short-term anti-estrogen treatments, are dependent onNOTCH4
signaling that can be blocked by combination treatment with a
NOTCH4 inhibitor.
To further substantiate this finding, we analyzed MFE and
ALDH activity of MCF-7, T47D, and ZR-75-1 cells treated for
3 days with tamoxifen or fulvestrant in combination with
RO4929097. In all cases, RO4929097 reduced MFE and
ALDH-positive cells (Figures 3D and 3E). To confirm that
RO4929097 reduced the tumor-initiating capacity, we conduct-
ed in vivo limiting dilution transplantation of MCF-7 cells.
Extreme limiting dilution analysis (ELDA) revealed an 11-fold
enrichment in tumor-initiating cell frequency following tamoxifen
or fulvestrant pre-treatment, which was reversed by co-treat-
ment with RO4929097 (Figure 3F). Inhibition of NOTCH4 cleav-
age/activation by RO4929097 was evidenced by decreased
HEY1 and HES1 mRNA and protein levels (Figures 3G and 3H).
Thus, we established, using PDX models and cell lines in tu-
mor-initiating cell assays, that NOTCH4 inhibition reduces
BCSC activity induced by anti-estrogen treatment.
NOTCH4 Inhibition Targets CSCs in TAMR PDX Models
The next question we asked was whether inhibiting NOTCH4
signaling to target BCSCs will overcome long-term acquired
anti-estrogen resistance in ER+ BC patients. We investigated
RO4929097 treatment in two established PDXs (HBCx22 and
HBCx34) that have long-term acquired resistance to tamoxifen
in vivo. Analysis of HES1 expression by immunohistochemistry
revealed that these two TAMR PDXs displayed increased NotchFigure 3. NOTCH4 Inhibition using RO4929097 Abrogates Tamoxifen a
(A–C) Early (HBCx34) and metastatic (Met) (BB3RC31) PDX tumors treated in vivo
kg/week, subcutaneous injection) in the presence or absence of the NOTCH4 inh
ALDH-positive cells. (C) Secondary tumor formation. 100,000 cells of metastatic
slow-release estrogen pellets. Tumor growth (>100 mm3) was determined at day
(D and E) MCF-7, T47D, and ZR-75-1 cells were pre-treated in adherence with 10
(10 mM; hatched bars) or DMSO (filled bars) for 72 hr. (D) MFE and (E) percentag
(F–H) MCF-7 cells were pre-treated in adherence for 6 days in the presence of R
were carried out in NSGmice with 90-day slow-release estrogen pellets. Tumor g
for growth/mice tested for each cell number tested. ELDA of tumor-initiating cell
compared to the control. (H) HES1 protein expression levels determined by wes
Data are represented as mean ± SEM. p values refer to hatched bars compared
See also Figures S3 and S4.
Cell Repsignaling activation compared to the parental control (Figure 4A).
Notably, the TAMRHBCx34 PDXmodel has a higher percentage
of MFE and ALDH activity than the endocrine-sensitive HBCx34
PDX model (compare Figures 1F and 1G with Figures 4B and
4C). These data suggest that acquired tamoxifen resistance in
PDX models involves enrichment for BCSC activity through
Notch signaling. Treatment with RO4929097 for 14 days demon-
strates that MFE and ALDH activity can be significantly reduced
in TAMR PDX tumors in vivo (Figures 4B–4D).
NOTCH4/HES/HEY Gene Signature Predicts for
Resistance to Tamoxifen Treatment and Prognosis in
ER+ Tumors
Based on the aforementioned observations, we hypothesized
that NOTCH4 activity, comprising a NOTCH4/HES/HEY gene
signature, would predict for response to tamoxifen treatment.
In gene expression data from 669 pre-treatment tumors from
four published Affymetrix microarray datasets of ER+ patients
who subsequently received adjuvant tamoxifen therapy, we
found NOTCH4, HES1, HEY1, and HEY2 to be co-expressed in
some tumors, as demonstrated in the heatmap ordered from
left to right by the sum of the four genes (Figure 5A). Importantly,
elevated expression of these Notch genes before treatment was
significantly associated with distant metastasis (Figure 5A) and
with reduced overall survival in an independent cohort of 343
untreated ER+ patients (Figure 5B). Thus,NOTCH4 gene expres-
sion and activity in tumors before treatment with endocrine ther-
apy predicts sensitivity to treatment, indicating that this signaling
pathway predicts de novo as well as acquired endocrine resis-
tance. These data strengthen the case for therapies against
NOTCH4 to target the endocrine-resistant ALDH-positive cells
responsible for relapse of ER+ tumors following hormonal ther-
apy (Figure 5C).
DISCUSSION
Here, we report that BCSC activity and frequency are increased
in response to the common endocrine therapies tamoxifen and
fulvestrant in ER+ patient samples and in early and metastatic
PDXs. Our findings suggest that endocrine therapies do not
target BCSCs, and this may explain how residual drug-resistant
cells are responsible for the relapse of ER+ tumors following hor-
monal therapy. Although we observe increased BCSC frequency
after endocrine treatments, we do not know whether absolute
BCSC numbers remain the same and are selected for or whethernd Fulvestrant Enrichment of CSC Activities
for 14 days with tamoxifen (10 mg/kg/day, oral gavage) or fulvestrant (200 mg/
ibitor RO4929097 (3 mg/kg/day, oral gavage). (A) MFE (%). (B) Percentage of
(BB3RC31) PDX were re-implanted subcutaneously in NSG mice with 90-day
90 after cell injection.
6 M tamoxifen (red bars) and 107 M fulvestrant (blue bars) with RO4929097
e of ALDH-positive cells were assessed after pre-treatments.
O4929097 (10 mM; hatched bars) or DMSO (filled bars). (F) In vivo experiments
rowth (>100 mm3) was assessed at day 60 and is represented as mice positive
frequency is shown. (G) Expression of HEY1 and HES1 by real-time PCR was
tern blot.
to filled control bars. *p < 0.05; **p < 0.01.
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Figure 4. HBCx22 and HBCx34 TAMR PDXs Express High Levels of HES1
NOTCH4 inhibitor RO4929097 targets CSCs in tamoxifen-resistant (TAMR) PDXs.
(A) Representative micrographs and quantification of HES1 expression determined by immunohistochemistry. Scale bars, 100 mm.
(B–D) HBCx22 and HBCx34 TAMR PDXs treated in vivo for 14 days in the presence or absence of the GSI RO4929097 (10 mg/kg/day, oral gavage). (B) MFE (%).
(C) Percentage of ALDH-positive cells. (D) Representative FACS plots of ALDEFLUOR assay. ALDH-positive cells were discriminated from ALDH-negative cells
using the ALDH inhibitor DEAB.
Data are represented as mean ± SEM. *p < 0.05; **p < 0.01.
See also Figure S4.they can be induced by anti-estrogen treatment. Tamoxifen and
fulvestrant are clearly successful in reducing BC recurrence in
some patients. In other patients with poorer outcome after endo-
crine therapies, we demonstrate that tumors have high pre-treat-
ment levels of ALDH1 expression and NOTCH4 activation.
Moreover, we found that treating ER+ BC cells with endocrine
therapies specifically increases JAG1-NOTCH4 signaling and
that combining endocrine therapies with a Notch pathway inhib-
itor can prevent BCSC enrichment induced by endocrine thera-1974 Cell Reports 12, 1968–1977, September 29, 2015 ª2015 The Apies. Thus, our findings in patient-derived BCSCs establish that
JAG1 ligand signaling through the NOTCH4 receptor in ALDH-
positive cell populations is a determining factor in the acquisition
of endocrine resistance.
The best described strategy for inhibition of Notch signaling is
the use of small-molecule GSIs, which prevent the release of
Notch ICD (NICD). In our study, the GSI RO4929097 specifically
targets NOTCH4 cleavage in anti-estrogen-treated cells and,
thus, decreases BCSC activity in vitro (MFE and ALDH activity)uthors
AC
B Figure 5. NOTCH4 Receptor Activity Pre-
dicts for Resistance to Tamoxifen Treat-
ment and Prognosis in ER+ Tumors
(A and B) NOTCH4, HES1, HEY1, and HEY2 genes
in ER+ primary tumors from (A) tamoxifen-treated
or (B) untreated patients are co-expressed in the
heatmap ranked from left to right using the four-gene
signature. Colors are log2 mean-centered values;
red indicates high, and green indicates low. All
significant cut-points (p < 0.05) are shown in gray.
Kaplan-Meier analysis using the optimum cut-point
(dashed white line) demonstrates that elevated
expression of the Notch genes is significantly asso-
ciated with an increased rate of (A) distant metas-
tasis and (B) decreased overall survival. Vertical bars
onsurvival curves indicate censoredcases. p values
are based on a log-rank (Mantel-Cox) test.
(C) Diagram suggesting that endocrine therapies
do not target BCSCs and emphasizing the need of
targeting residual drug-resistant cells to eliminate
all cancer cells and prevent long-term recurrences
of ER+ BC.and tumor initiation in vivo. Our investigations in ER+PDX tumors
provide the rationale for the use of NOTCH4 inhibitors together
with endocrine therapies in the adjuvant or advanced settings
(Figure 5C). Significantly, we demonstrated the utility of
RO4929097 to target BCSCs in pre-clinical models of TAMR pa-
tient tumors.
In conclusion, our data establish that tamoxifen and fulves-
trant select for stem cell activity in short- and long-term-
treated BC cells, as well as in early endocrine therapy naive
and metastatic-endocrine-treated patient-derived samples and
PDXs. Importantly, we report that low numbers of stem cells
and low Notch signaling activation in patient tumors predict
response to tamoxifen therapy and better survival. Overall, these
results suggest that ER+ BC recurrence after endocrine
therapies, which target the majority of cells (ER+ cells), will be
reduced by targeting the JAG1+/NOTCH4+/ALDH1+/ER
BCSC population.
EXPERIMENTAL PROCEDURES
Patient-Derived Samples
Early BC samples were collected in RPMI (GIBCO), dissected into 1- to 2-mm3
cubes and digested with the Human Tumor Dissociation Kit (Miltenyi Biotec)Cell Reports 12, 1968–1977, Sepfor 2 hr at 37C. Digested tissue was filtered
sequentially through 100- and 40-mmcell strainers,
then centrifuged at 300 3 g for 5 min and washed
in PBS.
Metastatic samples (ascites or pleural effusions)
were centrifuged at 1,000 3 g for 10 min at 4C.
The cell pellets were diluted in PBS. Erythrocytes
and leucocytes were removed using Lymphoprep
(Axis-Shield) and CD45-negative magnetic sorting
(Miltenyi Biotec), respectively. Cells were cultured
in adherence for 7–9 days in DMEM/F-12 medium,
GlutaMAX (GIBCO) with 10% fetal bovine serum
(FBS; GIBCO), 10 mg/ml insulin (Sigma-Aldrich),
10 mg/ml hydrocortisone (Sigma-Aldrich), and
5 ng/ml epidermal growth factor (EGF; Sigma-Al-drich), in 106 M 4-OH tamoxifen (Sigma-Aldrich, H7904), 107 M fulvestrant
(ICI 182,780, Tocris, 1047), or ethanol (control).
Clinico-pathological details of the samples are summarized in Tables S1
(primary BC) and S2 (metastatic BC).
Please refer to the Supplemental Experimental Procedures for further
details.
PDXs and In Vivo Experiments
Mouse studies commenced in 8- to 12-week-old female mice and were con-
ducted in accordance with the UK Home Office Animals (Scientific Proce-
dures) Act 1986, using NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice. All in vivo
work was performed with a minimum of n = 4 mice per condition.
Serial passaging of the PDX was carried out by implanting small fragments
of the tumor subcutaneously into dorsal flanks of NSG mice. Early (HBCx34)
and metastatic (BB3RC31) BC estrogen-dependent PDXs were administered
with 8 mg/ml of 17-beta estradiol in drinking water at all times and were treated
with drugs when tumors reached 200–300 mm3. Experiments were performed
using PDX tumors between passages 5 and 8. Animal weight and tumor size
was measured bi-dimensionally using callipers twice a week.
Tamoxifen citrate (Sigma, T9262, 10 mg/kg/day) and RO4929097 (Cellagen
Technology, 3 mg/kg/day) were administered by oral gavage (0.1 ml per dose)
on a basis of 5 days out of 7 (weekends excluded) for 14 days. Tamoxifen
citrate and RO4929097 were prepared in 1% carboxymethylcellulose
(Sigma, C9481) dissolved in distilled water. Fulvestrant (kindly provided by
AstraZeneca, 200 mg/kg/week) was administered by subcutaneous injectiontember 29, 2015 ª2015 The Authors 1975
(0.1 ml per dose) on a weekly basis for 14 days. The HBCx22 and HBCx34
TAMR PDXs were treated for 14 days in the presence or absence of the GSI
RO4929097 (10 mg/kg/day, oral gavage). Xenografts were collected in ice-
cold DMEM for live-cell assays, histological analysis, and RNA and protein
extraction. PDX single-cell suspension was obtained using a collagenase-hy-
aluronidase mixture for digestion (Stem Cell Technologies).
Please refer to the Supplemental Experimental Procedures for further
details.
Mammosphere Colony Assay
MFE was calculated by dividing the number of mammospheres formed
(R50 mm) by the original number of single cells seeded (500 cells per square
centimeter for primary cells) and is expressed as fold change normalized to
control or as the mean percentage of MFE (Shaw et al., 2012).
Please refer to the Supplemental Experimental Procedures for further
details.
Tamoxifen Trial Study
Premenopausal BC patients with invasive stage II disease were enrolled in
SBII:2a, a Swedish clinical trial in which patients were randomly assigned to
receive 2 years of adjuvant tamoxifen or no treatment (control) and followed
up for recurrence-free and overall survival (Ryde´n et al., 2005). Our data
represent cumulative survival for a cohort of 322 premenopausal ER+ BC pa-
tients stratified by ALDH-low (below median) and ALDH-high (above median)
expression over time.
Notch Gene Expression Signature
The gene expression data on 669 ER+ tamoxifen-treated tumors (GSE6532,
GSE9195, GSE17705, and GSE12093) and 343 ER+ untreated tumors
(GSE2034 and GSE7390) are from published Affymetrix microarray datasets.
Please refer to the Supplemental Experimental Procedures for additional
details.
Statistical Analysis
If not stated otherwise, a two-tailed Student’s t test was performed for statis-
tical analysis. A value of p < 0.05 was considered to be statistically significant.
Error bars represent the SEM of at least three independent experiments. Data
are shown as mean ± SEM.
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